Results 41 to 50 of about 2,124,017 (159)
Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation
Frontiers in Cardiovascular Medicine, 2020 Tricuspid regurgitation (TR) has a not negligible prevalence and its severity is correlated with poorer outcomes. However, surgical options are rarely offered to these patients because of their high surgical risk.
Antonio Mangieri +12 more
doaj +1 more source
Advanced Intelligent Systems, EarlyView.A unifying device–cardiovascular interface framework is presented to classify implantable cardiovascular technologies as intracardiovascular blood‐contacting systems or extracardiovascular tissue‐only and blood‐handling architectures. Cross‐class comparison across shared semiquantitative criteria, including blood‐contact burden, biomimicry ...
Bergo Nicolò +7 more
wiley +1 more source
Combined Transcatheter Tricuspid and Pulmonary Valve Replacement. [PDF]
, 2020 For patients with combined tricuspid and pulmonary valve disease, operative intervention carries high mortality risk. Published reports of combined transcatheter tricuspid and pulmonary valve replacement have been limited to single cases.A retrospective ...
Small, Adam J +5 more
core +1 more source
Valve-in-Ring Transcatheter Heart Valve for Severe Tricuspid Regurgitation
JACC: Case Reports, 2019 We report the case of a man with recurrent decompensated right-sided heart failure secondary to severe tricuspid regurgitation after tricuspid annuloplasty.
Leigh A. Cummins, MBBS +3 more
doaj +1 more source
Early Experience With Evoque Transcatheter Tricuspid Valve Replacement in Carcinoid Heart Disease
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Tricuspid regurgitation (TR) is nearly universal in carcinoid heart disease (CHD), but surgical replacement carries significant risk, and CHD was excluded from the landmark TRISCEND II trial. We present seven patients with CHD undergoing Evoque transcatheter tricuspid valve replacement (TTVR) at two tertiary centers.
Jackson S. Burton +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Current state of transcatheter tricuspid valve repair [PDF]
, 2020 Tricuspid regurgitation (TR) is a common valvular heart disease affecting >1.6 million people in the United States (US) and >70 million people worldwide.
Elmariah, Sammy, Kolte, Dhaval
core +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
Transcatheter Therapies for Treating Tricuspid Regurgitation.
, 2016 Tricuspid valve (TV) disease has been relatively neglected, despite the known association between severe tricuspid regurgitation (TR) and mortality. Few patients undergo isolated tricuspid surgery, which remains associated with high in-hospital mortality
Lauten A +9 more
core +1 more source
Frontiers in Cardiovascular Medicine, 2021 Transcatheter techniques for the treatment of tricuspid regurgitation (TR) are being more frequently used and several new devices are in development.
Nina C. Wunderlich +6 more
doaj +1 more source